SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Ray Charles

PatientRay Charles
Date of birth1960-09-23
IdentifiersMRN HR-ML009-SYN; SSN (made up) 000-09-5561
Document date2026-03-31
AuthorGloria Fenwick, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week follow-up, seen the same day by ophthalmology for the blind eyes. [S]

History of Present Illness

Mr. Charles is a 65-year-old man, blind since childhood, with an opioid use disorder in sustained remission for more than thirty years, who returns four weeks after his first visit and is seen by ophthalmology on the same day. His eyes have been comfortable, with no pain, redness, discharge, or headache around the eyes. He picked up the naloxone nasal spray; the pharmacy put a braille label on the box and now gives audio labels for any medicine. He received his first-visit summary and results as an accessible electronic document and read them with his screen reader. He has had no opioid or other drug use and no cravings, and he has been touring as usual. He has had no falls. [S]

ElementDetail
EyesComfortable; no pain, redness, or discharge
RecoveryNo use and no cravings
NaloxoneDispensed with a braille label
AccessibilityVisit summary received and read with his screen reader
FallsNone

Review of Systems

SystemResultFinding
EyesNegativeNo eye pain, redness, discharge, or headache around the eyes
PsychiatricNegativeMood good; no cravings; no thoughts of suicide or self-harm
MusculoskeletalNegativeNo falls, joint pain, or back pain

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrilsOne spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response, and call 911Nasal route2026-03-03activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-31Body height178cmS
2026-03-31Body weight80.2kgS
2026-03-31Body mass index (BMI) [Ratio]25.3kg/m2S
2026-03-31Systolic blood pressure126mm[Hg]S
2026-03-31Diastolic blood pressure76mm[Hg]S
2026-03-31Heart rate66/minS
2026-03-31Respiratory rate14/minS
2026-03-31Body temperature36.6CelS
2026-03-31Oxygen saturation in Arterial blood by Pulse oximetry98%S

Physical Exam

Vital signs recorded on 2026-03-31; see the Vital Signs section. [S]

SystemFinding
GeneralAlert, warm, and witty. Each step of the examination described before it was done
EyesNo light perception. Lids and ocular surfaces quiet, with no redness, swelling, or discharge; ophthalmology examined him today
PsychiatricEuthymic; organized thought; no signs of intoxication or withdrawal

Problems

ProblemClinical statusVerificationCodeProvenance
Blindness of both eyes since childhood, no light perception; cause never diagnosedactiveconfirmed H54.0X55S — Synthetic modern coding of the documented childhood blindness; category 5 (no light perception) is a synthetic grading of what the sources call blindness.
Opioid use disorder (heroin), in sustained remission for more than thirty years, without medication treatmentactiveconfirmed F11.21S — Synthetic modern coding of the publicly admitted heroin addiction and his documented recovery; listed as an active problem because it is managed at every visit, with remission carried by the code.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationComprehensive eye examinationYearly for blind eyes, or with symptomsCompleted todayOphthalmology examination today: no light perception; quiet, comfortable eyes; no active disease
ExaminationEye comfort and ocular surface check: pain, redness, dischargeEvery visitCompleted todayNo pain, redness, or discharge; ocular surfaces quiet
ExaminationTonometry (eye pressure)Every glaucoma visit; for blind eyes, only if pain or rednessNot indicatedNo light perception and no pain; ophthalmology advises measuring only if pain or redness develops, because lowering pressure cannot help vision
ImagingOCT, optic disc imaging, and visual fieldsEvery 6 to 12 months in sighted glaucomaNot indicatedNot informative without light perception
ExaminationGonioscopy and central corneal thicknessAt baseline in glaucomaNot indicatedWould not change care in blind, painless eyes
Medication safetyEye-drop adherence and side effectsEvery visitNot indicatedNo eye drops
Self-managementTeaching about eye red flags (pain, redness, headache around the eye)At diagnosis and each eye visitCompleted todayHe knows to seek same-day care for eye pain, redness, discharge, or headache around the eye
SurveyDepression screen (PHQ-9)At intake, at six months, and yearlyUp to datePHQ-9 2 four weeks ago; mood good today
SurveySuicide-risk review and safety plan, with the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in his phone
SurveyMood Disorder QuestionnaireAt a new depressive episodeNot indicatedNo depressive episode
Self-managementRecovery check: any return to use, cravings, triggers, and supportsEvery visitCompleted todayNo return to use and no cravings; work and long-time friends remain his supports
Medication safetyNaloxone at home and when travelingAt intake; check expiry at each visitCompleted todayDispensed with a braille label; one for home and one for travel
SurveyDrug-use screen (DAST-10)YearlyUp to dateDAST-10 0 four weeks ago
SurveyAlcohol screen (AUDIT-C)YearlyUp to dateAUDIT-C 2 four weeks ago
LaboratoryHepatitis C, hepatitis B, and HIV testingAt entry to care for a person with a substance use disorderDeferredNot offered at intake, a deviation from the VA/DoD guidance. He has no symptoms, so no harm is evident. Corrective action: hepatitis C, hepatitis B, and HIV testing to be drawn with his consent at the annual wellness visit, together with the Medicare preventive tests
Medication safetyMedication for opioid use disorderOffered to every person with active opioid use disorderNot indicatedSustained remission for more than thirty years without medication; he knows that buprenorphine and methadone are available if he ever needs them
LaboratoryUrine drug testingDuring treatment for active opioid use disorderNot indicatedNot used in long sustained remission without treatment; it would add nothing and could feel stigmatizing
Self-managementWritten plan for any future acute pain or surgeryBefore any planned procedure, and once in remissionDueTo be written with him at the next visit
Self-managementAccessible documents and communicationEvery visitCompleted todaySpoken orientation and description of each step; visit summary sent as an accessible electronic document
Medication safetyMedicine labeling in braille or audioWith every new prescriptionCompleted todayBraille label on the naloxone; audio labels from the pharmacy
ExaminationCDC STEADI fall-risk screenEvery visit from age 65Completed todayNo falls; steady gait; Timed Up and Go 10 seconds four weeks ago
ReferralOphthalmology consultationOnce, then yearlyCompleted todaySeen today
ReferralVision rehabilitation services (orientation and mobility, assistive technology)Offered to anyone with vision loss, and again with any changeCompleted todayOffered by ophthalmology today; he has long-established skills and does not want them now
Self-managementAdvance care planningYearly from age 65DueAt the annual wellness visit in the autumn
Self-managementVaccinationsYearly, per the CDC scheduleDueInfluenza vaccine given last autumn; others reviewed at the annual wellness visit

Goal progress:

Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Primary Open-Angle Glaucoma Preferred Practice Pattern (2025); Vision Rehabilitation Preferred Practice Pattern (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, glaucoma and depression, bipolar, and mood disorders monographs (2026)

Follow-up: Three-month review. Same-day visit for eye pain or redness. Yearly ophthalmology review. Next scheduled visit 2026-06-02: three-month review of recovery, accessibility, and fall prevention. [S]